How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Hepatitis A Virus Cellular Receptor 2 Market
- By Product Type: Monoclonal Antibodies, Recombinant Proteins, ELISA Kits, PCR Kits, Cell Lines
- By Application: Diagnostic Research, Therapeutic Development, Vaccine Research, Drug Screening, Basic Research
- By End User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Clinical Laboratories, Contract Research Organizations (CROs), Government Research Laboratories
- By Technology: Immunoassay, Molecular Cloning, Flow Cytometry, Western Blotting, Cell Culture Techniques
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Monoclonal Antibodies leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 8 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 265 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 8 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Hepatitis A Virus Cellular Receptor 2 Market report
A complete, evidence-based study - 11 chapters and 111 sections covering market size, segmentation across 4 axes, regional analysis and 8 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Application 5
End User 5
Technology 5
Companies profiled
Aurigene Discovery Technologies Ltd
BeiGene Ltd
Eli Lilly and Co
Enumeral Biomedical Holdings Inc Incte Corp
Interprotein Corp
Jounce Therapeutics Inc Merus NV
Novartis AG
Sorrento Therapeutics Inc Sutro Biopharma Inc Tesaro Inc Trellis Bioscience Inc
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
8 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Aurigene Discovery Technologies Ltd
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →BeiGene Ltd
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Eli Lilly and Co
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Enumeral Biomedical Holdings Inc Incte Corp
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Interprotein Corp
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Jounce Therapeutics Inc Merus NV
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Novartis AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.191 →Sorrento Therapeutics Inc Sutro Biopharma Inc Tesaro Inc Trellis Bioscience Inc
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.196 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$9,293M by 2033 · 6.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Monoclonal Antibodies48.0
- Recombinant Proteins8.7
- ELISA Kits15.3
- PCR Kits18.9
- Cell Lines9.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,822M → $3,379M · 8.0%
Europe$1,270M → $2,222M · 7.2%
Asia Pacific$1,159M → $1,756M · 5.3%
Latin America$717.7M → $1,206M · 6.7%
Middle East and Africa$552.0M → $870.8M · 5.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.682026
6.682027
6.712028
6.712029
6.722030
6.742031
6.752032
6.762033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Aurigene Discovery Technologies Ltd14.2
- BeiGene Ltd18.5
- Eli Lilly and Co8.5
- Enumeral Biomedical Holdings Inc Incte Corp11.5
- Interprotein Corp9.7
- Jounce Therapeutics Inc Merus NV9.6
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type12.2%
Application22.7%
End User28.6%
Technology36.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.8
- Europe23.6
- Asia Pacific18.6
- Latin America12.8
- Middle East and Africa9.2
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Aurigene Discovery Technologies Ltd | 95 | 81 | 89 | 77 | 79 | 94 | 86 |
| BeiGene Ltd | 89 | 68 | 73 | 79 | 82 | 68 | 77 |
| Eli Lilly and Co | 65 | 78 | 65 | 67 | 68 | 67 | 68 |
| Enumeral Biomedical Holdings Inc Incte Corp | 76 | 78 | 72 | 68 | 62 | 81 | 73 |
| Interprotein Corp | 57 | 60 | 64 | 55 | 56 | 75 | 61 |
| Jounce Therapeutics Inc Merus NV | 66 | 59 | 56 | 65 | 70 | 57 | 62 |
| Novartis AG | 56 | 61 | 62 | 43 | 44 | 59 | 54 |
| Sorrento Therapeutics Inc Sutro Biopharma Inc Tesaro Inc Trellis Bioscience Inc | 48 | 59 | 44 | 51 | 37 | 45 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Aurigene Discovery Technologies Ltd
- BeiGene Ltd
- Eli Lilly and Co
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Aurigene Discovery Technologies Ltd | ✓ | ✓ | ✓ | ✓ | ◐ | ✓ |
| BeiGene Ltd | ✓ | ◐ | − | ◐ | ✓ | ✓ |
| Eli Lilly and Co | ✓ | ✓ | ◐ | − | ◐ | ◐ |
| Enumeral Biomedical Holdings Inc Incte Corp | ✓ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Interprotein Corp | − | ◐ | ✓ | − | − | ◐ |
| Jounce Therapeutics Inc Merus NV | ◐ | − | ◐ | − | ◐ | ◐ |
| Novartis AG | − | ◐ | − | − | − | − |
| Sorrento Therapeutics Inc Sutro Biopharma Inc Tesaro Inc Trellis Bioscience Inc | − | ◐ | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Aurigene Discovery Technologies Ltd86
2BeiGene Ltd77
3Enumeral Biomedical Holdings Inc Incte Corp73
4Eli Lilly and Co68
5Jounce Therapeutics Inc Merus NV62
6Interprotein Corp61
7Novartis AG54
8Sorrento Therapeutics Inc Sutro Biopharma Inc Tesaro Inc Trellis Bioscience Inc47
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Aurigene Discovery Technologies Ltd
Challenger3
Strong scale, closing on the leaders.
BeiGene LtdEli Lilly and CoEnumeral Biomedical Holdings Inc Incte Corp
Contender2
Focused players with pockets of strength.
Interprotein CorpJounce Therapeutics Inc Merus NV
Niche2
Specialists in a single segment or region.
Novartis AGSorrento Therapeutics Inc Sutro Biopharma Inc Tesaro Inc Trellis Bioscience Inc
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across Hepatitis A Virus Cellular Receptor 2 Market — a $242M beachhead inside a $3.76B market.
Beachhead (SOM)$242Mobtainable near-term
Serviceable (SAM)$1.31Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Monoclonal Antibodies
Best fit — highest urgency & budget in Product Type.
Economic buyer80 fit
Recombinant Proteins
Strong fit — clear ROI and a fast path to value.
End user66 fit
ELISA Kits
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel28%
Digital / self-serve20%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Hepatitis A Virus Cellular Receptor 2 Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified21%
Evaluation15%
Closed-won8%
$16.0KCAC
$67KLTV
4.2:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Hepatitis A Virus Cellular Receptor 2 Market is a high-growth opportunity — $1.35B by 2033, compounding at 10.6%.
TAM · 2025$601Mtoday
TAM · 2033$1.35Bforecast
CAGR10.6%2027–2033
Cumulative$8.38Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.35BTotal addressable market
SAM$523MServiceable available market
SOM$109MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.6% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
8+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.35BLarge & growingTAM by 2033 at 10.6% CAGR
$523MServiceable nowreachable with today’s model
$109MBeachhead winobtainable near-term share
8+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.05BBear6.9% CAGR
$1.35BBase10.6% CAGR
$1.73BBull14.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Hepatitis A Virus Cellular Receptor 2 Market — a $7.70B market by 2033. Plan: grow share from 6.7% to 11.6%.
Market size · 2033$7.70Btotal addressable
Market CAGR6.1%2027–2033
Target share11.6%from 6.7% today
Revenue ambition$893Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.7% | 11.6% | On track |
| Revenue | $529M | $893M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 31.1% | 41.8% | Ahead |
| Customer retention | 91.6% | 94.5% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $93M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Hepatitis A Virus Cellular Receptor 2 Market conversation — a $4.78B market you can size, segment and defend in minutes.
Market size · 2033$4.78Btotal opportunity
Growth6.7%CAGR to 2033
Addressable buyers984+accounts in scope
Typical ROI4.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.3×return on cost, year one
< 2 mopayback period
$65K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
8+players profiled in this market
Coverage includes
Aurigene Discovery Technologies LtdBeiGene LtdEli Lilly and CoEnumeral Biomedical Holdings Inc Incte CorpInterprotein CorpJounce Therapeutics Inc Merus NVNovartis AGSorrento Therapeutics Inc Sutro Biopharma Inc Tesaro Inc Trellis Bioscience Inc
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Hepatitis A Virus Cellular Receptor 2 Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Hepatitis A Virus Cellular Receptor 2 Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Hepatitis B Diagnostic Tests Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportHepatitis C Virus Envelope Protein E2 Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportHepatitis Viruses Diagnostic Tests Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportFlu Shots Market
Market size, share, segmentation and regional forecast.
$669M market · 2025 base year
View reportFlucloxacillin Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportFelbinac (CAS 5728-52-9) Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportGallbladder Cancer Therapeutics Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportExenatide Drugs Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportGallbladder Cancer Treatment Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportGALNT1 Antibody Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportGABA Receptor Agonist Drug Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportAir Driven Handpiece Turbines Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.